Haemonetics Stock Surged 30%, Here’s Why
Haemonetics (HAE)’s stock surged 32%, fueled not just by numbers—like a sharper margin and a soaring P/E multiple—but by market confidence sparked from strong Q3 results, an upbeat full-year outlook, and fresh analyst upgrades. What’s behind this momentum? Let’s dive deeper.
| 11052025 | 11062025 | Change | |
|---|---|---|---|
| Stock Price ($) | 50.7 | 67.1 | 32.3% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1,346.0 | 1,327.8 | -1.4% |
| Net Income Margin (%) | 12.1% | 12.7% | 4.4% |
| P/E Multiple | 14.9 | 19.0 | 27.1% |
| Shares Outstanding (Mil) | 48.1 | 47.6 | 1.1% |
| Cumulative Contribution | 32.3% |
So what is happening here? The stock price jumped 32%, driven by a 27% boost in P/E multiple and a 4.4% rise in net margin, despite a slight 1.4% dip in revenue. Let’s see what’s behind these shifts.
Before we get into details of events that led to stock surge, here is what market wisdom says: A single stock can be risky, but there is a huge value to a broader, diversified approach we take with the Trefis High Quality Portfolio. Separately, consider what the long-term performance for your portfolio could be if you combined 10% commodities, 10% gold, and 2% crypto with equities.
Here Is Why Haemonetics Stock Moved
- This Strategy Pays You 8.7% While Lining Up MPWR at Bargain Prices
- What Could Light a Fire Under Microsoft Stock
- 3 Key Risks That Could Drag Down Meta Platforms Stock
- Cash Machine Trading Cheap – Fiserv Stock Set to Run?
- Is Recursion Pharmaceuticals Stock Attractive?
- Comfort Systems USA Stock’s Winning Streak May Not Be Over Yet
- Strong Q3 Earnings: Haemonetics exceeded Q3 revenue and EPS estimates, reporting $327.3M and $1.27 EPS.
- Raised Full-Year Outlook: Management increased full-year adjusted EPS guidance and organic growth outlook.
- BofA Securities Upgrade: BofA Securities upgraded HAE to Neutral and raised price target to $75.00.
- BTIG Price Target Hike: BTIG maintained ‘Buy’ rating and raised price target to $88.00.
- Plasma Segment Strength: Plasma segment sales of $125.4M surpassed estimates, indicating market recovery.
Our Current Assesment Of HAE Stock
Opinion: We currently find HAE stock fairly priced. Why so? Have a look at the full story. Read Buy or Sell HAE Stock to see what drives our current opinion.
Risk: A quick way to gauge risk for HAE is by checking its past drops during major sell-offs. It slid about 41% in the Dot-Com crash and 39% during the Covid sell-off. The Global Financial Crisis saw a roughly 25% dip, while the 2018 correction wasn’t far off at nearly 30%. The Inflation Shock hit hardest, with a steep 69% low from its peak. Even with solid fundamentals, these swings show how much HAE can drop when markets get shaky.
HAE stock may have seen strong gains recently, but investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.